These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 28052855)

  • 1. The Oral β-Lactamase SYN-004 (Ribaxamase) Degrades Ceftriaxone Excreted into the Intestine in Phase 2a Clinical Studies.
    Kokai-Kun JF; Roberts T; Coughlin O; Sicard E; Rufiange M; Fedorak R; Carter C; Adams MH; Longstreth J; Whalen H; Sliman J
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28052855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonclinical Safety Assessment of SYN-004: An Oral β-lactamase for the Protection of the Gut Microbiome From Disruption by Biliary-Excreted, Intravenously Administered Antibiotics.
    Kokai-Kun JF; Bristol JA; Setser J; Schlosser M
    Int J Toxicol; 2016 May; 35(3):309-16. PubMed ID: 26700136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of ribaxamase (SYN-004), a β-lactamase, to prevent Clostridium difficile infection in β-lactam-treated patients: a double-blind, phase 2b, randomised placebo-controlled trial.
    Kokai-Kun JF; Roberts T; Coughlin O; Le C; Whalen H; Stevenson R; Wacher VJ; Sliman J
    Lancet Infect Dis; 2019 May; 19(5):487-496. PubMed ID: 30885591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolerability and Pharmacokinetics of SYN-004, an Orally Administered β-Lactamase for the Prevention of Clostridium difficile-Associated Disease and Antibiotic-Associated Diarrhea, in Two Phase 1 Studies.
    Roberts T; Kokai-Kun JF; Coughlin O; Lopez BV; Whalen H; Bristol JA; Hubert S; Longstreth J; Lasseter K; Sliman J
    Clin Drug Investig; 2016 Sep; 36(9):725-734. PubMed ID: 27283946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral Beta-Lactamase Protects the Canine Gut Microbiome from Oral Amoxicillin-Mediated Damage.
    Connelly S; Fanelli B; Hasan NA; Colwell RR; Kaleko M
    Microorganisms; 2019 May; 7(5):. PubMed ID: 31137766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Formulation development of SYN-004 (ribaxamase) oral solid dosage form, a β-lactamase to prevent intravenous antibiotic-associated dysbiosis of the colon.
    Bristol A; Hubert S; Hofmann F; Baer H
    Int J Pharm; 2017 Dec; 534(1-2):25-34. PubMed ID: 28986322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SYN-004 (ribaxamase), an oral beta-lactamase, mitigates antibiotic-mediated dysbiosis in a porcine gut microbiome model.
    Connelly S; Bristol JA; Hubert S; Subramanian P; Hasan NA; Colwell RR; Kaleko M
    J Appl Microbiol; 2017 Jul; 123(1):66-79. PubMed ID: 28245091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SYN-007, an Orally Administered Beta-Lactamase Enzyme, Protects the Gut Microbiome from Oral Amoxicillin/Clavulanate without Adversely Affecting Antibiotic Systemic Absorption in Dogs.
    Connelly S; Fanelli B; Hasan NA; Colwell RR; Kaleko M
    Microorganisms; 2020 Jan; 8(2):. PubMed ID: 31979034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ribaxamase, an Orally Administered β-Lactamase, Diminishes Changes to Acquired Antimicrobial Resistance of the Gut Resistome in Patients Treated with Ceftriaxone.
    Kokai-Kun JF; Le C; Trout K; Cope JL; Ajami NJ; Degar AJ; Connelly S
    Infect Drug Resist; 2020; 13():2521-2535. PubMed ID: 32801790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of SYN-004, an oral beta-lactamase treatment to protect the gut microbiome from antibiotic-mediated damage and prevent Clostridium difficile infection.
    Kaleko M; Bristol JA; Hubert S; Parsley T; Widmer G; Tzipori S; Subramanian P; Hasan N; Koski P; Kokai-Kun J; Sliman J; Jones A; Connelly S
    Anaerobe; 2016 Oct; 41():58-67. PubMed ID: 27262694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low dose oral beta-lactamase protects the gut microbiome from oral beta-lactam-mediated damage in dogs.
    Connelly S; Fanelli B; Hasan NA; Colwell RR; Kaleko M
    AIMS Public Health; 2019; 6(4):477-487. PubMed ID: 31909068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification, Characterization, and Formulation of a Novel Carbapenemase Intended to Prevent Antibiotic-Mediated Gut Dysbiosis.
    Connelly S; Parsley T; Ge H; Kaleko M
    Microorganisms; 2019 Jan; 7(1):. PubMed ID: 30654495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral Metallo-Beta-Lactamase Protects the Gut Microbiome From Carbapenem-Mediated Damage and Reduces Propagation of Antibiotic Resistance in Pigs.
    Connelly S; Fanelli B; Hasan NA; Colwell RR; Kaleko M
    Front Microbiol; 2019; 10():101. PubMed ID: 30804903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Orally administered beta-lactamase enzymes represent a novel strategy to prevent colonization by Clostridium difficile.
    Stiefel U; Nerandzic MM; Koski P; Donskey CJ
    J Antimicrob Chemother; 2008 Nov; 62(5):1105-8. PubMed ID: 18693236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity, pharmacokinetics, clinical efficacy, safety and pharmacoeconomics of ceftriaxone compared with third and fourth generation cephalosporins: review.
    Bijie H; Kulpradist S; Manalaysay M; Soebandrio A
    J Chemother; 2005 Feb; 17(1):3-24. PubMed ID: 15828439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Clinical Study Provides the First Direct Evidence That Interindividual Variations in Fecal β-Lactamase Activity Affect the Gut Mycobiota Dynamics in Response to β-Lactam Antibiotics.
    Delavy M; Burdet C; Sertour N; Devente S; Docquier JD; Grall N; Volant S; Ghozlane A; Duval X; Mentré F; d'Enfert C; Bougnoux ME;
    mBio; 2022 Dec; 13(6):e0288022. PubMed ID: 36448778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation in an animal model and in vitro of the combination clavulanic acid and cephalosporins against beta-lactamase producing and nonproducing Staphylococcus aureus strains.
    de Sá Del Fiol F; Rocha De Mattos Filho T; Groppo FC
    Braz J Infect Dis; 2000 Feb; 4(1):36-42. PubMed ID: 10788844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An engineered live biotherapeutic for the prevention of antibiotic-induced dysbiosis.
    Cubillos-Ruiz A; Alcantar MA; Donghia NM; Cárdenas P; Avila-Pacheco J; Collins JJ
    Nat Biomed Eng; 2022 Jul; 6(7):910-921. PubMed ID: 35411114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Mechanisms of resistance in Enterobacteriaceae towards beta-lactamase antibiotics].
    Susić E
    Acta Med Croatica; 2004; 58(4):307-12. PubMed ID: 15700687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Excretion of beta-lactam antibiotics in sweat--a neglected mechanism for development of antibiotic resistance?
    Hoiby N; Pers C; Johansen HK; Hansen H
    Antimicrob Agents Chemother; 2000 Oct; 44(10):2855-7. PubMed ID: 10991872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.